We examined the effects of physiologic infusions of arginine vasopressin (AVP) on cardiovascular hemodynamics and on reflex responses initiated by decreasing cardiopulmonary baroreceptor stimulation (with lower body negative pressure) in 10 healthy, captopril-pretreated young men (19-27 yr). Their responses were compared with those of four volunteers given isosmotic infusion. Heart rate, stroke volume, blood pressure, and forearm blood flow were measured by electrocardiography, impedance cardiography, radial artery cannulation, and strain gauge plethysmography. Two 55-min infusions of AVP at rates of 0.15 and 0.40 ng/kg per min increased average plasma concentrations from control levels of 5 pg/ml to 18 and 36 pg/ml, respectively. These infusions resulted in progressive reductions of heart rate and cardiac output and increases of forearm and total peripheral resistance. Blood pressure increases were significant only during the larger AVP infusion rate. Lower body negative pressure provoked reflex increases of total peripheral resistance. These increases were enhanced 60% during AVP infusion compared with increases during control (pre-AVP). Baseline measurements and reflex responses were unchanged by isosmotic infusions. These results demonstrate that AVP has profound effects on cardiovascular function and augments cardiopulmonary baroreflex-mediated increases of peripheral resistance in man.
Introduction
Studies from experimental animals demonstrate that elevations of plasma arginine vasopressin (AVP)' levels within the physiologic range have profound effects on cardiovascular function and autonomic reflexes (1) (2) (3) (4) (5) . There are very few reports of the cardiovascular effects of AVP infusion in man. Available evidence indicates that small increases of plasma AVP levels result in decreases of heart rate but do not change blood pressure (6) (7) (8) . When AVP is infused into patients with autonomic dysfunction or into normal subjects after ganglionic blockade, heart Please address correspondence to Dr. Ebert Receivedfor publication 29 January 1985 and in revisedform 3 December 1985.
1. Abbreviations used in this paper: AVP, arginine vasopressin; D5W, isosmotic; ECG, electrocardiograph; lbnp, lower body negative pressure; Zo, transthoracic impedance. rate does not decrease, but blood pressure increases substantially (7, 8) . These data suggest that the pressor effects of AVP are buffered by a neurally mediated bradycardia and a decline in cardiac output.
The influence ofAVP on cardiac output and total peripheral resistance in healthy man is not known. Despite numerous reports of the effect of AVP on cardiovascular function in experimental animals, we were not confident that similar effects occurred in conscious man since human autonomic neural control mechanisms differ from those ofother species (9, 10) . Therefore, one objective of this investigation was to determine the effects of increasing plasma AVP levels, within a physiologic range, on cardiac output and peripheral resistance in healthy man.
A second objective was to test the hypothesis that AVP alters human cardiopulmonary baroreflex control of peripheral resistance. This inquiry was prompted by previous data which have shown that AVP has both a direct effect of constricting vascular smooth muscle (11, 12) and a major influence on autonomic neural mechanisms in animals (2) (3) (4) (5) . Cardiopulmonary baroreceptors respond to slight alterations in central blood volume and initiate reflex changes in peripheral resistance to maintain a stable blood pressure (13, 14) . If AVP is released during hemorrhage or orthostasis (15, 16), it may have a profound effect on reflex resistance increases initiated by low-pressure baroreceptors.
Methods
These studies were approved by both institutions' Human Research Review Committee. 14 healthy normotensive adults were studied afterthey gave written consent to participate. Their (18) . A 100-kHz, 4-mA current was transmitted through the outer two electrodes and transthoracic impedance (Zo) changes were detected from the inner two electrodes. The first derivative of the Zo change (associated with ventricular contraction) was used to calculate stroke volume (18, 19) , and changes in baseline Zo were used to detect relative changes in intrathoracic fluid. It has been established in this laboratory (18, 19) (18) . The impedance method detected accurately stroke volume changes ranging from 1 to 100 ml/beat.
Total peripheral resistance was calculated from the ratio of impedance-derived cardiac output and arterial blood pressure. In this study, there was a significant correlation (r = 0.751, P < 0.01) between baseline total peripheral resistance and plasma norepinephrine, an index of sympathetic activity (27) . This strengthens our contention that impedancederived parameters are reliable.
Baseline Zo can be used as an index of thoracic blood volume. We reason that such estimates are accurate based upon the following: (a) changes in Zo correlate closely with changes of central blood volume in animals (28) (29) (30) ; (b) in this lab, changes of calf blood volume (produced by intermittent graded venous occlusions of the upper thigh), which are detected by impedance, correlate well (r = 0.87) with estimates made with an Hg-in-Silastic strain gauge; and (c) Zo changes correlate closely (r = 0.989) with reductions in central venous pressure produced by graded lower body negative pressure (31) .
Biochemical measurements. Blood samples were obtained from the arterial catheter and analyzed in the Bioassay Laboratory located in our Physiology Department. Norepinephrine and epinephrine were determined by radioenzymatic assay using the Cat-A-Kit (Upjohn Co., Kalamazoo, MI). Plasma renin activity was determined by radioimmunoassay (RIA) of the generation of angiotensin I using a modification of the technique developed by Sealy et al. (32) . Plasma AVP concentration was measured using an RIA procedure developed in this laboratory and described previously in detail (33, 34) . Plasma samples (1 ml), which were deproteinized with 2 ml acetone, were taken to complete dryness using a centrifugation-vacuum-concentrating system (Savant Instruments, Hicksville, NY) and assayed as reported previously. Protein precipitation of human plasma resulted in a 20-25% loss determined with both 1251I-AVP and AVP. Reported values were corrected for 23% extraction loss and therefore represent the concentrations in the original l-ml plasma sample. The between-assay variability based on 12 separate standard curves averaged ±4.4%. The intraassay coefficient of variation averaged ±4.0%. The least detectable AVP concentration in the original plasma averaged 0.3 pg/ml, and the mid-range of the assay averaged 6.5 pg/ml.
Protocol. Subjects abstained from alcohol, caffeine, and nicotine for 24 h before each study and fasted from midnight to 7 a.m. on the day ofthe study. They ate a light breakfast in the laboratory which consisted of a doughnut and 250 ml of orange juice. Volunteers were given 25 mg of captopril (E. R. Squibb & Sons, Princeton, NJ). This prevented fluctuations in angiotensin II which could have influenced responses to AVP infusion (35, 36) . Intravenous and radial artery catheters were inserted after local infiltration with lidocaine. Impedance electrodes, ECG electrodes, heart sounds microphone, and forearm strain gauge and cuffs were placed. Volunteers were positioned in the lower body negative pressure (Ibnp) box. A practice trial of 10 mmHg of Ibnp was initiated to familiarize each subject with this procedure. After a 45-min supine rest period, arterial blood was sampled for plasma renin activity, AVP, and catecholamines. This was followed by three brief (10-s), relaxed, endexpiratory breath holds (at 2-minintervals). Baseline (control) data were obtained from five cardiac cycles during each of these three periods of apnea and were averaged. This was followed by a 3-min period of lbnp (10 mmHg) during which 3-10 s breath hold samples were given captopril before the study, plasma renin activity was elevated from normal levels (which range between 1 and 2 ng/ml per h in supine men). Renin activity had begun to return toward baseline during the last 15 min of the study. Plasma epinephrine was unchanged throughout the testing protocol. However, norepinephrine tended to decrease at the low-dose AVP infusion and was significantly (P < 0.05) decreased from control during the larger dose of AVP. Plasma AVP (Fig. 2) , renin activity, and catecholamines were unchanged in the time control group. Plasma renin activity (ng/ml per h) and norepinephrine (pg/ml) averaged 8.7±1.8 and 205±18, respectively, during control. These were 8.5±2.6 and 216±18 during the first placebo infusion and were 7.1±3.1 and 222±21 during the second placebo infusion. (Fig. 3) . Baseline total peripheral resistance (1,018±96 dyne * sec cm-5) increased progressively to 1,195±117 and 1,333+104 dyne-sec cm-5 during low-dose and high-dose AVP infusion (Fig. 4) . A similar and significant progressive increase offorearm vascular resistance was noted. This figure also demonstrates that Zo, a reliable index of thoracic blood volume (31), was unchanged during AVP infusions.
Baseline hemodynamic parameters were minimally changed in the time control group, as shown in Fig. 2 . Analysis ofvariance demonstrated a significant (P < 0.05) effect of AVP on all variables (except Zo) when compared with the time controls.
Responses to low-level Ibnp. Heart rate and arterial blood pressure were unchanged by Ibnp both before and after AVP infusion (Fig. 5) . However, stroke volume and cardiac output were decreased significantly by lbnp and to a comparable extent during control and during AVP infusion. In contrast, the reflex increases oftotal peripheral resistance produced by lbnp (96±15 dyne sec * cm-5) were increased by 60% during low-and highdose AVP infusion (to 157±47 and 155±44 dyne-sec-cm-5, respectively; Fig. 6 ). AVP did not have a similar enhancing effect on reflex increases of forearm vascular resistance.
Zo was used to monitor the decreases in thoracic blood volume produced by lbnp. As shown in Fig. 6 control (pre-lbnp) total peripheral resistance for each subject was graphically related (linear regression) to the average change in total peripheral resistance produced by lbnp (Fig. 7) (Fig. 6 ). Figure 5 . Responses of 10 volunteers to 10 mmHg of lbnp. Heart rate and blood pressure were unchanged. Stroke volume and cardiac output declined significantly (**, P < 0.01); however, these declines were not different during AVP infusion compared with control (preinfusion) responses. similar during control, low-, and high-dose AVP infusion periods. This suggests that the stimulus to low pressure baroreceptors was similar during control and during both AVP infusion periods.
In a previous study, Myers and Honig (37) demonstrated that vascular resistance changes are influenced by the initial vessel diameter and tone. Since AVP increased baseline total peripheral resistance (Fig. 4) A VP action on cardiac function and peripheral resistance. The mechanisms whereby AVP lowered heart rate and cardiac output were not ascertained in the present study. Data from anesthetized animals have suggested that high pharmacologic doses of AVP can influence the heart by direct effects on the sino-aortic node and/or direct coronary vasoconstriction with an associated decrease of contractility (38) (39) (40) . At lower doses, similar to those used in this investigation, AVP increased vagal restraint on the heart by activation of the baroreflex (39, 40) . AVP may also act centrally to increase vagal-cardiac efferent activity. Intravertebral infusions of AVP in conscious dogs were noted to produce greater declines in heart rate compared with intravenous infusions, despite similar elevations ofplasma AVP levels (41) . Furthermore, since sino-aortic baroreceptor denervation abolishes AVP-induced bradycardia in dogs, it has been suggested that the central effects of AVP are modulated by an afferent baroreceptor activity (42) .
There are no previous studies in man which have examined the effects of small increases in plasma AVP on stroke volume. Impedance cardiography which reliably detects small changes in stroke volume, (18, 19, (22) (23) (24) revealed a significant 8% reduction in stroke volume during small physiologic elevations in plasma AVP. This response is most likely not related to an increased afterload since arterial blood pressure was minimally elevated. A decrease in preload was also probably not involved since Zo, an index of thoracic blood volume, was unchanged during AVP infusions.
AVP has potent direct effects on vascular smooth muscle. The concentration of AVP required to decrease rat mesenteric arteriolar wall diameter is only 1 pg/ml (1 1). Similar effects have been shown in larger blood vessels (43) . These direct effects appear to explain the dose-dependent increase in total peripheral resistance and forearm vascular resistance during AVP infusion. It is likely that resistance increases are not due to increases of efferent sympathetic activity since AVP infusion decreases plasma norepinephrine (this study) and decreases lumbar sympathetic nerve activity in rabbits (5) .
In this study, the cardiovascular effects of intravenous infusions ofAVP were not compared with those produced by other substances. It has been shown that angiotensin II infusions in man produce increases in heart rate, blood pressure, and peripheral resistance with little change in cardiac output (44) . This contrasts to our demonstration of bradycardia and virtually no pressor effects of AVP infusions.
Cardiopulmonary baroreflex function. Slight reductions in thoracic blood volume are sensed by cardiopulmonary baroreceptors on the low-pressure side of the circulation. Reflex responses consist of increases in forearm and splanchnic vascular resistance (13, 14) . These responses are thought to be independent of arterial baroreflexes since heart rate and blood pressure are unchanged in man (13, 14) . Furthermore, nonhypotensive hemorrhage in dogs activates cardiopulmonary baroreflexes without changing carotid sinus afferent traffic (45) .
In the present study, the reduction in cardiopulmonary baroreceptor stimulation by lbnp was similar before and during AVP infusion, as seen by the similar increases in Zo (an index of decreases of thoracic blood volume). Associated with this decreased stimulus to cardiopulmonary baroreceptors were significant reflex increases oftotal peripheral resistance and forearm vascular resistance. The increases in total peripheral resistance were augmented during AVP infusion. Furthermore, enhanced total peripheral resistance responses were augmented similarly during both infusion doses ofAVP, which suggests that this effect may be maximal at plasma AVP concentrations only slightly above baseline and below 20 pg/ml.
Augmented total peripheral resistance responses to lbnp did not appear to be due to a reflex enhancement offorearm vascular resistance since significant potentiation of responses by AVP were not seen in this bed. One study in anesthetized cats demonstrated a preferential effect of AVP on augmenting reflex vasoconstriction of intestinal vessels during hemorrhage (48) . It is possible that the reflex regulation of this vascular bed may be preferentially enhanced by vasopressin during lbnp. Furthermore, AVP may augment vasoconstriction by its reported effect on sympathetic ganglion, nerve terminals, and adrenergic receptors (l1, 12, 46, 47) .
A similar enhancing effect of AVP on resistance increases provoked by carotid baroreceptor hypotension in dogs has been observed by Cowley et al. (4) . This response may be related to a direct effect of AVP on carotid arterial vessels (43) . In anesthetized rabbits, increases in single fiber and whole nerve afferent traffic in response to carotid sinus pressure changes are augmented by AVP infusion (49) .
In this study, it is likely that arterial baroreceptors were not involved in the exaggerated resistance response to lbnp during AVP infusion. Heart rate was unchanged by lbnp both before and after vasopressin infusion, which suggests that arterial baroreflexes were not activated.
Angiotensin II can influence cardiovascular control mechanisms in man (50) and alter responses to AVP infusion in rats (35) . Therefore, captopril was given to prevent changes in plasma angiotensin II which may have occurred during AVP infusion or lbnp exposure. The elevation of plasma renin activity was used as an index of the effectiveness of the blockade of angiotensin converting enzyme. A previous study demonstrated that pressor responses to exogenous angiotensin I are inhibited for more than 4 h after smaller doses of captopril (51). Thus it is unlikely that changes in plasma angiotensin II influenced responses ascribed to AVP.
Captopril is also known to increase plasma bradykinin and prostaglandin E2 levels (52) . If 
